Skip to main content

The Week in Review - 13 February 2016

The Week in Review - 13 Feb 2016 covers:

1.    Acute sacrolilitis diagnosis by CT or bone scan; causes pyogenic, Brucella, crystals, neoplasia
2.    FDA Advisory Vote on Biosimilar
3.    Bisphosphonates are not associated with gastric or esophageal cancer
4.    Psoriatic arthritis risk of SIE and only 6% added risk when using a TNF inhibitor
5.    RWCS – Trajectory of improvement predicts remission success
6.    Dr. Joel Kremer's blog on the History of Methotrexate
7.    FDA Arthritis Advisory Hearing voted 21-3 in favor of approving CT-P13 as a biosimilar of its reference product Remicade – may lead to approval for RA, Psoriasis, Psoriatic arthritis, adult and pediatric Crohn
8.    2016 RWCS Proceedings – Highlights from Drs. Cush, Kavanaugh, Gladman, Bergman, Troum

  • SURPRISE Study: add on vs single therapy with Tocilizumab
  • Polyarticular JIA – not a good idea to withdraw therapy
  • Very Early RA responds best in the AVERT study – Abatacept + MTX.
  • Psoriasis review by Dr. Gladman
  • Debate on Medical Marijuana
  • OA IA steroid injections are not effective 
  • Stricter warnings for NSAIDs and CV risk
  • Lesinurad is FDA approved as cotherapy for gout
  • Gout co-associations 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow